burden. The association between the DDS and the selected covariates was also assessed. Results: A total of 373 patients in China, 157 in Japan, and 141 in South Korea were enrolled from July 2011 to July 2013. Mean ± standard deviation duration (years) of T2D differed across countries (China 11.4 ± 7.5; Japan 13.8 ± 8.7; South Korea 15.7 ± 8.8; P\0.0001). Japanese 
INTRODUCTION
Type 2 diabetes (T2D) is a chronic progressive disease and is a major public health problem worldwide. Sustained hyperglycemia, measured by glycosylated hemoglobin A1c level (HbA1c), can result in preventable complications that affect health and quality of life and are costly for health care systems [1, 2] . The prevalence of T2D in Asia is substantial and is increasing over time, with recent estimates suggesting that the prevalence of diabetes is 9.3% in China, 7.6% in Japan, and 7.3% in South Korea [3] .
Based on clinical trial results, insulin is the most effective glucose-lowering therapy and can improve quality of life by preventing hyperglycemia and reducing diabetic complications [4, 5] . International guidelines recommend that insulin treatment may be modified over time to achieve HbA1c targets [6] , which are\7% (\53 mmol/mol) in Japan [7] and China [8] and\6.5% (\48 mmol/mol) in South Korea [9] ; however, although most patients with T2D have HbA1c levels above these targets, many do not progress their insulin treatment (i.e., switch from basal to a mixed insulin regimen, add bolus doses, and/or increase dosing frequency) [10] [11] [12] . Overall, preliminary evidence suggests that various clinical and psychosocial factors prevent insulin progression at the patient, provider, and health care system levels [13] . As for patients, barriers may include fear, pain, concern over weight gain and/or disease progression, and inconvenience associated with injections [14, 15] . For the physician and health care system, barriers may include concerns over hypoglycemia, lack of experience, lack of qualified personnel, and lack of reimbursement for medicines or services [11, 14, 16] . Although the health burden of T2D is increasing in East Asia, only a few studies have actually examined patterns and trends of insulin progression or barriers associated with insulin treatment and its intensification in this population [17, 18] . [19] .
Within this study, data from MOSAIc patients from three countries, China, Japan, and South Korea, have been investigated at baseline and longitudinally over 2 years to identify patterns and trends of insulin treatment and progression as well as its associated barriers with insulin progression. Thus, this first of two articles presents the baseline demographic, clinical, treatment, and psychosocial characteristics of Japanese, Chinese, and South Korean MOSAIc patients, while cross-sectional data of treatment progression and attitudes toward therapy will be analyzed separately.
METHODS

Study Design
The rationale and design of the MOSAIc study have been reported elsewhere [13] . MOSAIc is a multinational, non-interventional, prospective, and observational cohort study. [21] . In addition, the study team developed survey tools for MOSAIc [13] 
RESULTS
A total of 373 patients in China, 157 in Japan, and 141 in South Korea were evaluated. Baseline demographic and clinical characteristics varied among patients in the three countries (Table 1) .
A significantly higher proportion of female patients was observed in China (56.0%) compared with the proportions in Japan (38.9%) and South Korea (36.2%) (P\0.0001). The mean (±SD) age differed significantly between countries, with the highest age in Japan (64.3 ± 12.7 years) and the lowest in China (60.8 ± 10.2 years).
Similarly, the mean (±SD) duration of diabetes also differed, being longer in South Korea (15.7 ± 8.8 years) than in China (11.4 ± 7.5 years) and in Japan (13.8 ± 8.7 years) (P\0.0001). Korea was once-daily basal insulin, whereas the most common regimen in China was twice-daily mixed insulin (Table 2 ).
In terms of PROs, the DDS (mean ± SD) scores differed significantly across countries, with South Korean patients reporting greater DDS scores (43.3 ± 16.6) than those from China (28.1 ± 10.6) and Japan (31.5 ± 13.5) ( There were no notable differences among East Asian patients regarding the association Baseline demographic and clinical characteristics varied among the three countries. This variability may be due to differences in the timing of insulin initiation in the patient's diabetes treatment regimen or differences in treatment patterns after insulin initiation, although our country-specific results were generally similar to those in other studies [23] [24] [25] [26] . In terms of gender, the proportion of female patients in China (56.0%) was higher than one in Japan (38.9%) and South Korea (36.2%) in our study; the gender distributions in each country were consistent with the other country-specific large observational research on insulin usage, though epidemiologically there was more male population in the whole T2D patients in each country [27] [28] [29] .
Furthermore, the higher incidence of diabetes-related complications in patients in South Korea compared with those in China and Japan may be related to more severe disease, as suggested by the longer mean duration of diabetes, we observed in South Korean patients. In addition, the different levels of access to tertiary-level hospitals in the three countries may have affected the rate of detection and accounted for some of the differences in reported proportions of some diabetes-related complications. The insulin regimens used by MOSAIc patients also differed among the three countries; markedly fewer Chinese patients were initiated on basal insulin compared with Japanese and South Korean patients. Local guidelines in China and Japan do not recommend specific insulins for initiation, and the choice of insulin relies largely on the health care provider's discretion [26, 30] . In South Korea, there are no treatment guidelines; however, recommendations suggest that a patient commences on basal insulin if HbA1c\8.5% (\69 mmol/mol) and mixed insulin if HbA1c C8.5% (C69 mmol/mol) [31] . Possible explanations for the infrequent use of basal insulin in China include the higher cost of this therapy compared with short-acting and mixed insulin, which may be prohibitive to patients [32] ; differing levels of reimbursement for insulin products, for example, short-acting insulin, premixed insulin, and Neutral Protamine Hagedorn insulin are on the Chinese National Essential Medicines list and are usually fully reimbursed by the insurance system [33] ; and the tendency for Chinese physicians to choose mixed insulin to manage both fasting and high postprandial plasma glucose resulting from the high-carbohydrate diets of Chinese patients [34] . The 2-year MOSAIc follow-up data will provide further information as to how these differences in insulin therapy in China will affect treatment progression.
A notable result of our study is the marked difference in treatment choices made by physicians from three countries, with patients in Japan being prescribed significantly more AHAs compared with patients in China or South Korea. These results reflect the differences in reimbursement and medicine access in East class is reimbursed in both Japan and South Korea and available in China, the use of these medicines is expected to increase in these countries, demonstrating the pivotal role access and reimbursement has in enabling patient treatment across the region [35] .
Differences in baseline quality of life and diabetes distress scores between patients from various countries may be explained in part by ethnic cultural differences. For example, it may explain why Japanese patients were less likely to report higher diabetes distress rates as a result of hypoglycemia compared with Chinese or South Korean patients. However, differences in treatment regimens and other factors, such as variations in the understanding of definitions of hypoglycemia, may also contribute to this finding. In contrast to other findings published in the literature [36, 37] , our baseline data results did not reflect that patients with a higher knowledge of diabetes reported a lower DDS. The longitudinal changes in quality of life and DDS as well as any impact on insulin progression and health outcomes will be reported in the second article of this series, which will describe the findings of the 2-year East Asian MOSAIc follow-up analyses.
The extensive MOSAIc observational, real-world, self-reported data will assist in identifying patient, provider, and health care environmental factors that influence insulin regimens among T2D patients in East Asia. The data reported that in this first of a two-part series provides a baseline and introduction for the 2-year study results. In addition, although other studies have examined real-world use of insulin therapy in East Asia, the MOSAIc study provides clinical and psychosocial analyses over a longer duration of follow-up, and is specifically aimed at addressing the current lack of evidence regarding insulin progression and the barriers to achieving optimal care in East Asia. However, the study does have some limitations. Study participants were volunteered to answer the questionnaires, because patients were not collected in random sampling; therefore, socio-demographic and psychological characteristics may not represent the whole population. Patient records were only available from physicians participating in the study, which may limit the collection of the data if the study patients were treated by additional health care providers. In addition, the observational study design prevented the inclusion of data beyond routine diabetes care or the control of country-specific variables that may have limited the ability to directly compare the countries. 
